News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Javelin Pharmaceuticals Comments on Tender Offer Extension by Hospira, Inc.
May 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV), a leading developer of novel acute care pain products, commented on the tender offer extension by Hospira, Inc.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
October 2, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together
October 2, 2025
·
2 min read
·
Tristan Manalac
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Genmab Buys Rising Cancer Star Merus for $8B
September 29, 2025
·
2 min read
·
Tristan Manalac
